longbridgelongbridge
  • Platform Features
    Features
    Investment ProductsPrivate Wealth ManagementTrading ToolsMarket Data ServicesAnalysis ToolsNews ServicesFor Developers
    Account Types
    For IndividualsFor Institutions
  • Café
longbridge
© 2026 Longbridge|Terms of ServicePrivacy Policy

Lepu Medical

300003

11.492.05% ( -0.24 )
Delay Closed: Sep 9, 15:00:00
Start trading
OverviewOverviewNewsNewsPostsPostsFinancialsFinancialsForecastForecastValuationValuationShareholdersShareholdersProfileProfile
LongbridgeAI

Current ValuationThe current P/E ratio is 27.49, within the reasonable range, cheaper than 60.91% of the time in the past 10 years, and the industry ranks 17/65, the industry Median 27.49.

27.49xP/E
¥11.49Stock price
¥0.42Earnings per share
27.49xP/E
Stock price¥11.49Earnings per share¥0.42

Historical Valuation

P/E ratioTypical rangeMedian
P/E ratio
29.94x
Typical range
21.87x–49.29x

Peer P/E ratio Comparison

It displays how the company's P/E ratio compares to top companies within its industry.
Industry median 27.49x
013263952

Industry P/E ratio Comparison

This shows the distribution of companies by P/E ratio range and their projected earnings per share growth for the next fiscal year.
Industry median 27.49x
0x30x60x90x120x150x
P/E ratio
Name/Symbol
300760SZMindray
25.46x1.70%¥200.19B
002223SZYUYUE MEDICAL
22.97x0.70%¥25.77B
300003SZLepu Medical
27.49x16.83%¥21.18B
002901SZDouble Medical
23.51x13.61%¥16.66B
603014SHWeigao Blood Purification
26.72x2.19%¥13.14B
300529SZJAFRON
23.39x18.12%¥12.28B
600587SHSHINVA
17.96x--¥7.65B
300206SZEdan
19.01x--¥6.71B
301367SZBMC
26.18x27.60%¥5.78B
688236SHChunli Medical
19.16x0.00%¥5.33B
300326SZKinetic Medical
19.76x--¥4.45B
688410SHSWS Medical
23.48x45.87%¥4.35B
688581SHAGS
19.22x79.57%¥4.11B
688580SHVISHEE
24.03x20.83%¥4.06B
301033SZMedprin
29.78x--¥3.65B
688358SHCHISON MEDICAL
26.76x17.31%¥3.10B

Risk Warning

Timeframes using financial data from S&P Global. The feature provides key metrics such as price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S) ratios, and dividend yield. For reference only and does not constitute investment advice.